[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"China Medical University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":618},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,66,0,25,[9,45,62,91,124,154,176,196,222,246,272,294,313,334,352,379,406,428,448,478,503,526,548,574,598],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641262","effect-of-chinese-herbal-medicine-on-kidney-function-in-non-diabetic-ckd-100641262",false,"NCT07657338","Effect of Chinese Herbal Medicine on Kidney Function in Non-Diabetic CKD","Effects of Chinese Herbal Medicine as an Adjunctive Therapy on Renal Function in Patients With Non-Diabetic Chronic Kidney Disease: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Patients diagnosed with stage 3-4 chronic kidney disease (CKD), confirmed by a nephrologist and classified as ICD-10-CM codes N18.3-N18.4.\n* Ability to understand the study procedures and provide written informed consent.\n* Willingness to comply with study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Acute kidney injury or major kidney-related surgery within 3 months prior to enrollment.\n* Participation in another clinical trial within 3 months that may affect renal function.\n* Alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal.\n* Pregnancy or breastfeeding.\n* History of diabetes mellitus.\n* Malignancy currently receiving chemotherapy, radiotherapy, or other systemic anticancer treatment.\n* End-stage disease defined under palliative care regulations.\n* Known allergy to any components of the CKD-1 herbal formula, including Astragalus membranaceus, Salvia miltiorrhiza, Poria cocos, Moutan cortex, Scutellaria baicalensis, Lonicera japonica, or Alisma orientale.","ALL","18 Years",{"count":5,"type":20},"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a randomized controlled pilot trial designed to evaluate the effects and safety of a traditional Chinese medicine formula (CKD-1) as an add-on therapy to standard treatment in patients with stage 3-4 non-diabetic chronic kidney disease. Eligible participants will be randomly assigned to receive either standard care alone or standard care combined with CKD-1 for 12 weeks. Kidney function, urine protein levels, and quality of life will be assessed before and after the intervention. The study aims to provide preliminary evidence on whether CKD-1 can improve renal function and quality of life in this patient population.",[26],"Non-diabetic Chronic Kidney Disease",[28,29,30,31],"Traditional Chinese Medicine","non diabetic chronic kidney disease","Adjunctive Therapy","Pilot Randomized Controlled Trial","NOT_YET_RECRUITING","2026-06-15",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":20},"2026-06-11",{"date":40,"type":20},"2026-12-31",{"name":42,"class":43},"China Medical University Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":61,"locationsCount":44},"100641084","effect-of-chinese-herbal-medicine-on-renal-function-in-diabetic-kidney-disease-100641084","NCT07657351","Effect of Chinese Herbal Medicine on Renal Function in Diabetic Kidney Disease","Effects of Chinese Herbal Medicine as an Adjunctive Therapy on Renal Function in Patients With Diabetic Kidney Disease: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Patients diagnosed with type 2 diabetes mellitus and stage 3-4 chronic kidney disease (CKD), confirmed by a nephrologist and classified as ICD-10-CM codes E11.21-E11.29 combined with N18.3-N18.4, consistent with diabetic kidney disease (DKD) definitions.\n* Ability to understand the study procedures and provide written informed consent.\n* Willingness to comply with study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Acute kidney injury or major kidney-related surgery within 3 months prior to enrollment.\n* Participation in another clinical trial within 3 months that may significantly affect renal function.\n* Alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal.\n* Pregnancy or breastfeeding.\n* History of malignancy currently receiving chemotherapy, radiotherapy, or other systemic anticancer treatment.\n* End-stage disease as defined under palliative care regulations.\n* Known allergy to any components of the DKD-1 herbal formula, including Astragalus membranaceus, Salvia miltiorrhiza, Chinese yam, Poria cocos, Moutan cortex, Schisandra chinensis, or Smilax glabra.",{"count":5,"type":20},[23],"This study is a randomized controlled pilot trial designed to evaluate the effects and safety of a traditional Chinese medicine formula (DKD-1) as an add-on therapy to standard treatment in patients with Diabetic Kidney Disease (DKD). Eligible participants will be randomly assigned to receive either standard care alone or standard care combined with DKD-1 for 12 weeks. Kidney function, glycemic control, proteinuria, quality of life, and traditional Chinese medicine tongue features will be assessed before and after the intervention. The study aims to provide preliminary evidence on whether DKD-1 can improve renal function, glycemic control, and quality of life in this patient population.",[56],"Diabetic Kidney Disease",[28,56,30,31],{"date":35,"type":36},{"date":38,"type":20},{"date":40,"type":20},{"name":42,"class":43},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":44},"100623242","assessing-clinical-impact-of-ai-for-iron-deficiency-100623242","NCT07394088","Assessing Clinical Impact of AI for Iron Deficiency","Evaluation of the Clinical Impact of Machine Learning-Based Risk Classification Using Blood Analysis on Iron Deficiency Detection","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Patients attending outpatient clinics of participating departments including 2.1. Internal Medicine, 2.2 Family Medicine 2.3. Hematology\u002FOncology\n3. Completion of a routine complete blood count (CBC) as part of usual clinical care during the outpatient encounter.\n4. Availability of the CBC report in the institutional laboratory information system, allowing sufficient data for analysis.\n\nExclusion Criteria:\n\n1. Encounters with missing or incomplete key identifiers (e.g., patient identification number, ) that prevent determination of exposure status (AI information displayed vs not displayed) or assessment of outcomes within the defined follow-up period.\n2. Encounters without a valid department code required by the information system to trigger the randomization mechanism and AI risk display.\n3. Encounters with incomplete or missing laboratory data required to activate the AI system.\n4. Repeated CBC encounters from the same patient during the study period, if applicable; only the first eligible encounter will be included to avoid duplication.",{"count":70,"type":20},2196,[23],"The goal of this clinical trial is to evaluate whether an AI-based risk notification system integrated into routine clinical care can improve the clinical detection of iron deficiency in adult patients attending Internal Medicine, Family Medicine, and Hematology\u002FOncology clinics at China Medical University Hospital in Taiwan.\n\nThe main questions this study aims to answer are:\n\n1. Does displaying AI-generated iron deficiency risk classification to physicians increase the overall detection rate of iron deficiency at the population level?\n2. Does the AI-based risk notification influence physicians' diagnostic behavior by increasing the rate at which ferritin testing is ordered specifically for suspected iron deficiency?\n3. Among ferritin tests ordered for suspected iron deficiency, does the diagnostic yield (positivity rate) remain appropriate, reflecting efficient use of testing resources?\n4. Are the effects of the AI-assisted intervention consistent among patients with anemia and without anemia?\n\nComparison Groups Researchers will compare clinical encounters in which physicians receive AI-generated iron deficiency risk information (the Prompt Group) with encounters in which physicians receive standard laboratory results without AI risk display (the Control Group). The comparison focuses on differences in iron deficiency detection, ferritin ordering behavior for suspected iron deficiency, and diagnostic yield.\n\nWhat Participants Will Experience\n\n1. No Additional Procedures:\n\n   As this is a pragmatic study embedded in routine clinical care, participants will not undergo any additional blood draws, invasive procedures, or clinic visits beyond standard care.\n2. Routine Care Only:\n\n   Patients attend their scheduled outpatient visits and receive complete blood count (CBC) testing as ordered by their treating physician, independent of study participation.\n3. Background Data Integration:\n\n   The AI system operates within the hospital's information system, analyzing routinely collected CBC data after results become available. No additional data entry or action is required from patients.\n4. Physician Autonomy Preserved:\n\nThe AI provides a non-mandatory risk classification as decision support. For patients identified as high risk, the system may display an informational prompt suggesting consideration of iron-related testing if no recent testing is found. All diagnostic and management decisions remain entirely at the discretion of the treating physician.",[74,75],"Iron Deficiency","Iron Deficiency Anemias",[77,78,79,80,81],"machine learning","complete blood count","iron deficiency","pragmatic randomized trial","detection rate","RECRUITING","2026-05-21",{"date":85,"type":36},"2026-05-26",{"date":87,"type":36},"2026-04-01",{"date":89,"type":20},"2027-03",{"name":42,"class":43},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":44},"100610829","digital-technology-for-active-and-healthy-ageing-in-taiwan-100610829","NCT07232667","Digital Technology for Active and Healthy Ageing in Taiwan","Healthy Taiwan Cultivation Plan: Building an Active-ageing Lifestyle in Rural Taiwan Through Integrating Novel Healthcare Technology - From Mitigating Digital and Health Literacy Gap, Establishing a Mobile Interactive Pro-active-ageing Information Platform, to Exploring Multi-dimensional Digital Biomarkers of Ageing","Inclusion Criteria:\n\n1. Currently living or receiving care in a stable environment for at least four weeks prior to enrollment:\n\n   * For community-based participants: must have resided at the same address for ≥4 weeks.\n   * For day-care participants: must have attended activities at the same dementia or elderly day-care center for ≥4 weeks.\n2. Able and willing to participate in the study procedures.\n3. Informed consent must be obtained before participation.\n\n   * If the participant's cognitive function has declined to a level that prevents self-consent, written consent will be obtained from a legally authorized representative or primary caregiver.\n\nExclusion Criteria:\n\n1. Unstable physical or psychological condition that makes participation unsafe, as determined by a clinical investigator - e.g., acute delirium or current respiratory infection (including COVID-19).\n2. Any known allergy or skin sensitivity to the materials used in the Geneactiv actigraphy device or iCue sensor pad.\n3. Any other medical, neurological, or behavioral condition deemed unsuitable for participation by the study physician.",true,"60 Years",{"count":101,"type":20},140,"2 Weeks","OBSERVATIONAL","Taiwan is entering a super-aged society in 2025, with more than 20% of the population aged 65 years or older. This rapid demographic shift, combined with increasing rates of chronic diseases, frailty, and dementia, has created growing challenges for healthcare and caregiving systems. Yunlin County, particularly its coastal region, has been one of Taiwan's earliest super-aged areas, showing higher rates of diabetes (10.5%), hypertension (28%), hyperlipidemia (26%), dementia (8%), and depression (12%) compared with national averages. Lifestyle factors such as tobacco (30%), betel nut (8%), and alcohol (15%) use are also more prevalent among local residents.\n\nFrom 2022 to 2024, health screenings at CMU Beigang Hospital revealed a 36.1% abnormality rate among 12,222 visits, while another 5,965 assessments from the county's ICOPE program showed similarly high rates. Many older adults, particularly retired agricultural and fishing workers, experience sedentary lifestyles and polypharmacy-related risks, which worsen frailty, insomnia, depression, and cognitive decline. Low general and digital health literacy further limits their ability to adopt preventive behaviors, forming a vicious cycle between poor health and aging.\n\nTo address these challenges, the Ministry of Health and Welfare launched the \"Healthy Taiwan Cultivation Plan.\" In alignment with this initiative, this project-led by CMU Beigang Hospital in collaboration with the National Health Research Institutes-aims to develop a wearable- and mobile-based health promotion model for rural older adults. The study will integrate research-grade actigraphy (Geneactiv), a mobile health platform (\"iMED\"), and the in-bed sensor iCue to monitor behavior, promote active aging, and enhance health and digital literacy. Ultimately, this project seeks to establish Taiwan's first integrated digital aging database and identify digital biomarkers for predicting cognitive and functional decline in older adults.",[106,107],"Healthy Aging","Digital Health Literacy",[109,110,111,112,113,114,115],"Elderly people","Wearable technology","Digital health literacy","Healthy aging","Health literacy","Digital gap","Digital biomarkers","2026-05-15",{"date":118,"type":36},"2026-05-18",{"date":120,"type":36},"2026-04-22",{"date":122,"type":20},"2029-12-31",{"name":42,"class":43},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100593184","phase-1-a-study-of-the-boron-neutron-capture-therapy-bnct-using-b10-l-bpa-in-malignant-brain-tumors-100593184","NCT07003139","A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors","A Phase I\u002FII Study to Evaluate Safety and Efficacy of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA as Boron Carrier in Malignant Brain Tumors.","Inclusion Criteria:\n\n1. Age of 18 years and older.\n2. Patients with malignant brain tumors confirmed by histological and\u002For medical imaging, classified as WHO Grade 3 or 4 according to the World Health Organization of tumors of the central nervous system (CNS) classification, excluding those with histologically confirmed Grade 3 intracranial ependymoma, medulloblastoma, and primary CNS lymphoma.\n3. There must be a time interval ≥ 3 months between prior radiation therapy and the scheduled BNCT.\n4. There must be a time interval ≥ 1 month between receipt of antitumor drugs and the scheduled BNCT.\n5. Within 4 weeks prior to the screening visit, measurable disease by magnetic resonance imaging (MRI) and\u002For computed tomography (CT) scan showing a volume ≦ 250 cm\\^3, longest dimension \\\u003C 7 cm.\n6. At least one measurable lesion that can be assessed by RECIST v1.1.\n7. Eastern Cooperative Oncology Group (ECOG) Performance Score ≤ 2.\n8. Life expectancy ≥ 3 months in the opinion of the investigator.\n9. Adequate organ functions as defined below:\n\n   * Hemoglobin ≥ 8.0 g\u002FdL.\n   * White blood cell (WBC) count ≥ 2.5 x 10\\^3\u002FμL.\n   * Neutrophil count ≥ 1.5 × 10\\^3\u002FμL.\n   * Platelet count ≥ 80 × 10\\^3\u002FμL.\n   * Aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN).\n   * Alanine aminotransferase (ALT) ≤ 2.5 × ULN.\n   * Serum creatinine ≤ 1.5 × ULN\n   * Estimated glomerular filtration rate(eGFR) ≥ 15 mL \u002F min \u002F 1.73m\\^2\n10. Female subjects with reproductive potential must have a negative result of serum pregnancy test at the screening visit and urine pregnancy test before the B10 L-BPA administration. However, if the subject has been menopausal for at least 2 years (more than 24 months since the last menstrual period) or uses surgical birth control, testing is not required.\n11. Female subject with childbearing potential as well as male subject with reproductive potential must agree to refrain from unprotected sex and use 2 methods of highly effective contraception with their partner (e.g. barrier contraceptives \\[male condom, female condom, or diaphragm plus spermicide\\], intrauterine device, hormonal methods \\[hormone shot or injection, implants, combination oral contraceptives, or patches\\]) for ≥ 6 months after the BNCT until the end of this study.\n12. Physically and mentally capable of participating in the study and willing to adhere to study procedures.\n13. Provision of signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with malignant brain tumors complicated by any of the following conditions:\n\n   * Extracranial metastases.\n   * Multiple intracranial lesions on both sides.\n2. The investigator assesses that the subject has concurrent infections or other malignant tumors and is not suitable to participate in the trial.\n3. Patients with malignant brain tumors are considered eligible for standard surgical treatment that is effective against the tumor.\n4. A time interval less than 3 months from previous radiation therapy for intracranial region.\n5. A time interval less than 3 months from last brain surgery (excluding drainage procedures and biopsy) and less than 1 month from previous chemotherapy.\n6. The adverse event of previous anti-tumor therapy were NCI-CTCAE V5.0 grade evaluation ≧ Class 3 (excluding alopecia and peripheral neuropathy).\n7. Received or expect to receive any investigational drug, biologic or device within 1 month prior to the scheduled BNCT.\n8. Patients receiving or expected to receive vascular endothelial growth factor inhibitors (except bevacizumab) or live attenuated vaccines within 1 month prior to the scheduled BNCT.\n9. Patients received major surgery within 1 month prior to the scheduled BNCT or are still recovering from a previous surgery. The investigator will evaluate the subject's condition when the subject receives major surgery. Major surgery is defined as procedure that requires general anaesthesia and\u002For anticipated hospitalization longer than 24 hours, with significant risk of blood loss or complications. Examples include heart surgery, organ transplants, and prolonged operations such as certain back surgeries. Procedures such as stent implantation, biopsy, endoscopy, and day surgery are excluded.\n10. Patients who had radiation myelitits or radiation necrosis of the brain\u002Fbrain stem.\n11. Patient who is prone to vascular rupture during the trial as assessed by the investigator. The Patient will be eligible for the study if they have undergone stent implantation and obtained consent from the investigator.\n12. Patients with severe congestive heart failure or renal failure, as well as myocardial infarction, unstable angina, or poorly controlled arrhythmia within 6 months prior to the scheduled BNCT.\n13. Severe comorbidities, including but not limited to poorly controlled epilepsy, poorly controlled diabetes mellitus, poorly controlled hypertension; chronic lung diseases (e.g., obstructive pneumonia, interstitial pneumonia, pulmonary fibrosis, and severe emphysema); kidney diseases (e.g., chronic renal failure, acute renal failure and nephrotic syndrome); cardiac diseases (e.g., New York Heart Association \\[NYHA\\] Functional Classification Class III or IV); phenylketonuria; and\u002For other severe conditions in the opinion of the investigator.\n14. Suspected or known hypersensitivity (including allergy) to boron or any component of the study drug or contrast media.\n15. Subject with hereditary fructose intolerance.\n16. With a cardiac pacemaker or will interfere with MRI-based or CT-based dose-planning or tumor response evaluation.\n17. Restless subjects who are unable to lie or sit in a cast for more than 30 minutes.\n18. Any medical or psychiatric conditions that, in the opinion of the investigator, may interfere with optimal participation in the study or place the subject at increased risk of adverse events (AEs).\n19. Female subject who is planning to be pregnant or lactating during the study period.\n20. Subject who is considered unfit to participate in the clinical study as assessed by the investigator.\n21. Subject who has received prior BNCT.",{"count":132,"type":20},10,[134,135],"PHASE1","PHASE2","This Phase I\u002FII study, titled 'A Phase I\u002FII Study to Evaluate Safety and Efficacy of the Boron Neutron Capture Therapy (BNCT) using B10 L-BPA as Boron Carrier in Malignant Brain Tumors.', aims to assess the efficacy of B10 L-BPA with BNCT in patients with malignant brain tumors. The primary objective is to evaluate the safety and efficacy of BNCT with B10 L-BPA for malignant brain tumors treatment, using the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) as the standard for assessment.",[138],"Malignant Brain Tumors",[140,141,142,138,143,144],"L-4-(10B)Boronophenylalanine","(10B)-4-Borono-L-phenylalanine","BNCT","Boron Neutron Capture Therapy","Borofalan (10B)","2026-05-11",{"date":147,"type":36},"2026-05-13",{"date":149,"type":36},"2025-06-30",{"date":151,"type":20},"2026-12",{"name":42,"class":43},2,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":44},"100560241","phase-1-adscs-therapy-in-patients-with-ctd-ild-100560241","NCT06574581","ADSCs Therapy in Patients With CTD-ILD","Allogenic Adipose Tissue Derived-MSCs Therapy in Patients With Connective Tissue Diseases-associated Interstitial Lung Disease(CTD-ILD): Phase I\u002FIIa Clinical Trial","Inclusion Criteria:\n\n1. Adult subjects aged between 20 and 80 years who meet the diagnostic criteria for connective tissue diseases such as dermatomyositis, polymyositis, scleroderma, systemic lupus erythematosus, rheumatoid arthritis, or Sjogren's syndrome.\n2. Subjects with refractory or progressive fibrotic interstitial lung disease: Subjects have been treated with steroids and potent immunosuppressants for more than 24 months with continued deterioration of lung function or lung lesions on CT scan (defined as a forced vital capacity (FVC) decline of more than 10% from baseline, an FVC decline of 5-10% with a diffusing capacity for carbon monoxide (DLCO) decline of more than 15% from baseline, or enlargement of lung lesions on CT scan) ; Or subjects with rapidly progressive interstitial lung disease: treated with high-dose steroids (above 0.8 mg\u002Fkg\u002Fday) and potent immunosuppressants for more than 3 months with continued deterioration of lung function or lung lesions on CT scan (defined as an FVC decline of more than 5% from baseline, a DLCO decline of more than 10% from baseline, or enlargement of lung lesions on CT scan); subjects with rapidly worsening condition: Onset of pulmonary symptoms within one month, gradual worsening of dyspnea and decreased blood oxygen levels, or enlargement of lung lesions.\n3. Subjects must have a well-established family support system confirmed by interviews with the principal investigator and social worker.\n4. Negative high-sensitivity urine pregnancy test before the trial.\n5. Agree to use effective contraceptive measures during the trial (e.g., taking contraceptive pills or using intrauterine devices one month before the trial).\n\nExclusion Criteria:\n\n1. Subjects who are unwilling to sign the informed consent form after detailed explanation by the physician.\n2. Patients younger than 20 or older than 80 years who show improvement in lung function or lung lesions on CT scan after 6 months of treatment with steroids and immunosuppressants.\n3. Women who are pregnant or breastfeeding, and women of childbearing age who do not use contraception.\n4. Subjects with abnormal liver function (serum GOT and GPT levels more than twice the upper limit of 40 units, except those caused by inflammatory myopathy) or poor kidney function (serum creatinine levels exceeding 1.4 units).\n5. Subjects with immune deficiencies such as HIV\u002FAIDS or other specific conditions (e.g., those diagnosed with notifiable infectious diseases as per Ministry of Health announcements).","20 Years","80 Years",{"count":164,"type":20},16,[134,135],"Connective tissue disease (CTD), an autoimmune and inflammatory disease, usually accompanied by lung interstitial\u002Falveolar inflammation and fibrosis (so called interstitial lung disease, ILD). The prevalence and mortality rate of CTD-ILD increase in recent several years. Although the use of corticosteroids and strong immunosuppressants can improve ILD in some patients with CTD, progressive lung fibrosis which needs lung transplantation and results in respiratory failure, even with mortality is observed. Currently, stem cell therapy is a breakthrough in the treatment of CTD-ILD, and the effective therapy with stem cells for patients with ILD have been reported.",[168,169],"Connective Tissue Diseases","Interstitial Lung Disease",{"date":147,"type":36},{"date":172,"type":36},"2024-08-20",{"date":174,"type":20},"2027-11-30",{"name":42,"class":43},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":162,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":193,"leadSponsor":195,"locationsCount":44},"100636032","phase-1-treatment-of-truncated-alk-positive-bone-cancer-using-crizotinib-xalkori-or-alectinib-alecensa-100636032","NCT07560410","Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)","Inclusion Criteria:\n\n* Age ≥ 20 years.\n* Patients with locally advanced or metastatic solid tumors harboring deficiency or alteration of anaplastic lymphoma kinase (ALK) tyrosine kinase.\n* Disease progression during or within 6 months after completion of standard therapy, or no appropriate standard treatment available.\n* At least one measurable lesion according to applicable response evaluation criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Estimated life expectancy of at least 8 weeks.\n\nExclusion Criteria:\n\n* Known hypersensitivity to crizotinib or alectinib.\n* Current or prior use of ALK inhibitors.\n* Current use of tyrosine kinase inhibitors.\n* Receipt of radiotherapy within 2 weeks prior to study entry. Palliative radiotherapy to non-target lesions is permitted.\n* History of other malignancies, except for osteosarcoma or chondrosarcoma, unless the patient has been disease-free for at least 2 years. Exceptions include adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* Liver cirrhosis with a Child-Pugh score ≥ 8.\n* Uncorrectable electrolyte abnormalities.\n* Presence of brain metastases.\n* Active acute infection.\n* Significant unresolved toxicity from prior therapy.\n* Comorbid conditions that may interfere with study participation, including but not limited to uncontrolled diabetes mellitus, autoimmune diseases, or any condition that, in the investigator's judgment, renders the patient unsuitable for the study.\n* Concurrent malignancy, unless it is adequately treated carcinoma in situ or basal cell carcinoma, or a malignancy that has been treated and has remained recurrence-free for at least 3 years.\n* Pregnant or breastfeeding women.\n* Patients with psychiatric disorders that may impair compliance with study requirements.\n* Current use of strong inducers or inhibitors of CYP3A enzymes, or use of other investigational or non-approved drugs.",{"count":132,"type":20},[134,135],"This is an investigator-initiated, single-center clinical trial evaluating the efficacy and safety of ALK inhibitors in patients with locally advanced or metastatic bone cancer harboring truncated ALK (ALKATI) alterations. Eligible patients must have disease progression after standard therapy or no suitable standard treatment options.\n\nParticipants will receive either crizotinib (Xalkori®) or alectinib (Alecensa®), with treatment selection determined by the study investigators. The study aims to assess antitumor activity, safety, and clinical outcomes in this rare molecular subtype of bone cancer.",[186],"Bone Cancer",[188,189],"bone cancer","Truncated ALK (ALKATI)","2026-05-05",{"date":145,"type":36},{"date":116,"type":20},{"date":194,"type":20},"2029-04-14",{"name":42,"class":43},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":98,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":221,"locationsCount":4},"100633362","the-effects-of-combining-electronic-picture-books-with-rpg-based-gamified-learning-on-nursing-students-motivation-and-learning-outcomes-in-breastfeeding-education-100633362","NCT07525700","The Effects of Combining Electronic Picture Books With RPG-Based Gamified Learning on Nursing Students' Motivation and Learning Outcomes in Breastfeeding Education","Inclusion Criteria:\n\n1. It is expected to include 100 people.\n2. A third-year nursing student.\n3. Studying obstetrics and gynecology nursing this semester.\n4. Agree to participate in this study and sign the research consent form.\n\nExclusion Criteria:\n\n1. Students who are planning to take a leave of absence at the time of data collection.\n2. Students who have not taken obstetrics and gynecology nursing this semester or have taken it in the past.\n3. Students who are unable to use 3C products.",{"count":203,"type":20},100,[23],"This study aimed to explore the impact of electronic picture books combined with RPG on breastfeeding learning outcomes among nursing students. The study participants were third-year nursing students from a university in central Taiwan. A randomized controlled design was used, with the experimental group receiving electronic picture books combined with RPG, while the control group received traditional face-to-face instruction. Changes in students' breastfeeding knowledge, learning motivation, self-efficacy, and cognitive load were assessed. The expected results can provide a reference for innovative teaching models in nursing education and promote the future clinical application of breastfeeding.",[207,208,209],"Nursing Education Research","Nursing Students","Breastfeeding Education",[211,212,209,208,213,214],"nursing education","learning motivation","electronic picture books","RPG","2026-04-07",{"date":217,"type":36},"2026-04-13",{"date":219,"type":20},"2026-09-30",{"date":40,"type":20},{"name":42,"class":43},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":228,"minAge":161,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":153},"100631654","evaluation-of-the-efficacy-of-biobran-rice-bran-arabinoxylan-in-supporting-breast-cancer-chemotherapy-100631654","NCT07503496","Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy","Inclusion Criteria:\n\n* Breast cancer stage I-III\n\nExclusion Criteria:\n\n* pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements","FEMALE","65 Years",{"count":231,"type":20},96,[23],"This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy. The study will assess chemotherapy-related side effects, quality of life, tumor size, tumor antigens, and routine blood test parameters over 24 weeks of treatment.",[235,236,237],"Breast Cancer Stages I","Breast Cancer Stages II","Breast Cancer Stage III","2026-03-25",{"date":240,"type":36},"2026-03-31",{"date":242,"type":36},"2025-04-07",{"date":244,"type":20},"2026-08-31",{"name":42,"class":43},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":21,"phases":254,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":44},"100630016","effectiveness-and-efficiency-of-an-upper-limb-active-passive-exoskeleton-robot-in-patients-with-frozen-shoulder-100630016","NCT07482189","Effectiveness and Efficiency of an Upper Limb Active-Passive Exoskeleton Robot in Patients With Frozen Shoulder","Inclusion Criteria:\n\n\\-\n\n1\\. Patients aged 20 years or older diagnosed by a clinician with primary or secondary frozen shoulder or adhesive capsulitis:\n\n1. Patients diagnosed by a clinician with frozen shoulder or adhesive capsulitis in the stiff phase.\n2. The patient has a loss of at least 50% of passive joint range of motion (including of shoulder flexion, abduction, internal rotation, and external rotation) on the affected shoulder compared to the relatively healthy shoulder.\n\nExclusion Criteria:\n\n1. Individuals with osteoarthritis or other skeletal conditions of the shoulder joint.\n2. Individuals with any contraindications to treatment, such as joint fusion, severe osteoporosis, or symptoms of any peripheral nerve compression.\n3. Individuals with untreated joint dislocations, fractures, or tendon ruptures.\n4. Individuals who have received steroid injections within the month prior to the study.\n5. Individuals who are uncommunicated or cognitively impaired.\n6. Pregnant women.\n7. Patients who refuse recruitment will also be excluded.",{"count":253,"type":20},40,[23],"Frozen shoulder, also known as adhesive capsulitis, is a common chronic shoulder disorder with symptoms including shoulder pain, limitations in both active and passive range of motion, and muscle weakness, which significantly affects daily functional abilities. The investigator applied upper limb exoskeleton-assisted therapy. This experiment used a randomized controlled trial to assess the clinical rehabilitation effects of exoskeleton-assisted range of motion and resistance training on patients with frozen shoulder.",[257,258],"Adhesive Capsulitis of the Shoulder","Frozen Shoulder",[260,261,262,263,264],"Frozen shoulder","Adhesive capsulitis","Exoskeleton robots","Robot-assisted rehabilitation","Rehabilitation","2026-03-21",{"date":238,"type":36},{"date":268,"type":20},"2026-03-16",{"date":270,"type":20},"2027-03-15",{"name":42,"class":43},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":229,"enrollmentInfo":278,"targetDuration":4,"studyType":21,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":44},"100560224","phase-2-dual-modulation-of-sigma-1-and-nmda-receptors-in-the-treatment-of-schizophrenia-100560224","NCT06574360","Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia","Inclusion Criteria:\n\n* Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia\n* Are resistant to adequate treatments of at least two antipsychotics (excluding clozapine)\n* Remain symptomatic but without clinically significant fluctuation, while their antipsychotic doses are unchanged for at least 3 months and will be maintained during the period of the 8-week trial\n* PANSS total score \\>70\n* Hamilton Depression Rating Scale-17 items (HAMD) \\\u003C7\n* Are physically healthy and laboratory assessments (including blood routine, biochemical tests) are clinically insignificant.\n* Have sufficient education to communicate effectively and are capable of completing the assessments of the study.\n* Agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder\n* History of epilepsy, head trauma, central nervous system diseases or mental disorders other than schizophrenia (including major depressive disorder, bipolar disorders, persistent depressive disorder, obsessive-compulsive disorder)\n* Pregnancy or lactation\n* Inability to follow protocol",{"count":279,"type":20},90,[135],"sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancing agent can be better than an S1R agonist alone deserves study.",[283],"Schizophrenia",[283,285,286],"NMDA","sigma-1 receptor",{"date":288,"type":36},"2026-03-24",{"date":290,"type":36},"2024-09-23",{"date":292,"type":20},"2029-03",{"name":42,"class":43},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":229,"enrollmentInfo":300,"targetDuration":4,"studyType":21,"phases":302,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":44},"100457774","phase-2-combination-of-nmda-enhancing-and-anti-inflammatory-treatments-for-ultra-resistant-schizophrenia-100457774","NCT05240976","Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia","Inclusion Criteria:\n\n* Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia\n* Are treatment-resistant to standard treatments of at least two specific antipsychotics before clozapine treatment\n* Are receiving adequate trials of clozapine for more than 12 weeks but without satisfactory response\n* PANSS total score ≥ 70; SANS total score ≥ 40\n* Have sufficient education to communicate effectively and are capable of completing the assessments of the study\n* Agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder\n* History of epilepsy, head trauma, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study\n* Clinically significant laboratory screening tests (including blood routine, biochemical tests)\n* Pregnancy or lactation\n* Inability to follow protocol",{"count":301,"type":20},80,[135],"Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.",[283],[306,285,307],"Ultra-resistant schizophrenia","Inflammation",{"date":288,"type":36},{"date":310,"type":36},"2022-02-23",{"date":89,"type":20},{"name":42,"class":43},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":21,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":333,"locationsCount":44},"100443319","phase-2-early-intervention-of-prodromal-schizophrenia-using-an-nmda-enhancer-100443319","NCT05052853","Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer","Inclusion Criteria:\n\n* Individuals meeting Criteria of Prodromal Syndrome (at least one of the following: 1. attenuated positive symptoms; 2. brief intermittent psychotic symptoms; 3. genetic risk and deterioration).\n* Subjects remain symptomatic (scoring at least 20 on the Scale of Prodromal Symptoms \\[SOPS\\] total score) after the 6-week screening phase (which contains the health-promotion program) and before the 12-week drug-trial period.\n* Subjects may be receiving ongoing treatment with antipsychotic medications, or may be medication-free for at least 12 weeks.For the subjects who have already been on such medications, the medications need to be continued for at least 4 weeks before the screening phase and the doses need to be kept unchanged during the study period. For those who have not yet been on such medications, these medications are forbidden during the study period.\n* Subjects agree to participate in the study and provide written informed consent after complete description of the study. For the subject \\\u003C 20 years old, a parent also has to provide written informed consent.\n\nExclusion Criteria:\n\n* DSM-5 diagnosis of intellectual disability, substance (including alcohol) use disorder, schizophrenia, schizophreniform disorder, delusional disorder, schizoaffective disorder, substance\u002Fmedication-induced psychotic disorder, or psychotic disorder due to another medical condition.\n* History of epilepsy, head trauma, stroke, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study.\n* Clinically significant laboratory screening tests (including blood routine, biochemical tests)\n* Pregnancy or lactation\n* Inability to follow protocol","13 Years","45 Years",{"count":322,"type":20},48,[135],"Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.",[326],"Prodromal Schizophrenia",[283,328,285],"Prodrome",{"date":288,"type":36},{"date":331,"type":36},"2021-11-01",{"date":151,"type":20},{"name":42,"class":43},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":229,"enrollmentInfo":340,"targetDuration":4,"studyType":21,"phases":341,"briefSummary":342,"conditions":343,"keywords":344,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":44},"100419701","phase-2-monotherapy-of-an-nmda-enhancer-for-schizophrenia-100419701","NCT04745143","Monotherapy of an NMDA Enhancer for Schizophrenia","Inclusion Criteria:\n\n* Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia\n* Refuse or are unable to tolerate antipsychotics due to poor response or adverse effects\n* PANSS total score ≥ 60\n* Free of antipsychotic drugs for at least 1 week\n* Agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Current substance abuse or history of substance dependence in the past 3 months\n* History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study\n* Use of depot antipsychotic in the past 3 months;\n* Clinically significant laboratory screening tests\n* Pregnancy or lactation\n* Inability to follow protocol",{"count":301,"type":20},[135],"Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.",[283],[283,285,345],"Oxidative stress",{"date":288,"type":36},{"date":348,"type":36},"2018-01-01",{"date":350,"type":20},"2027-12",{"name":42,"class":43},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":360,"maxAge":361,"enrollmentInfo":362,"targetDuration":4,"studyType":21,"phases":364,"briefSummary":365,"conditions":366,"keywords":368,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":44},"100628702","ultra-processed-food-consumption-and-behavioral-disorder-and-cognitive-function-100628702","NCT07465081","Ultra-processed Food Consumption and Behavioral Disorder and Cognitive Function","Relationship Between Ultra-processed Food Consumption and Behavioral Disorder and Cognitive Function in Children and Adolescents: the Mediation Role of Plasticizer","UPF","Inclusion Criteria:\n\n* Participants must meet all of the following conditions:\n\nAge: 10-15 years old. Attention difficulties: Diagnosed with attention deficit hyperactivity disorder (ADHD) or identified as having learning difficulties based on a specialist's or teacher's recommendation.\n\nUltra-processed food consumption: Consumes at least six types or six servings of ultra-processed foods daily.\n\nExclusion Criteria:\n\n* Younger than 10 years old or older than 15 years old.","10 Years","15 Years",{"count":363,"type":20},154,[23],"The goal of this interventional study is to determine whether reducing ultra-processed food consumption in children and adolescents can improve cognitive function. The main question it aims to answer is:\n\nDoes reducing ultra-processed food consumption through online nutritional education improve cognitive function in children and adolescents with attention difficulties? Researchers will compare a nutritional education group to a non-intervention group to assess whether reducing ultra-processed food intake leads to cognitive improvement.\n\nParticipants will:\n\nAttend a weekly online nutritional education course for 12 weeks Be encouraged to replace ultra-processed foods with whole foods",[367],"ADD\u002FADHD",[369,367,370],"ultraprocessed food","nutritional education","2026-03-06",{"date":373,"type":36},"2026-03-11",{"date":375,"type":36},"2025-03-05",{"date":377,"type":20},"2026-07-31",{"name":42,"class":43},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":21,"phases":388,"briefSummary":389,"conditions":390,"keywords":393,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":44},"100628573","chinese-classics-recitation-training-in-subjective-cognitive-decline-100628573","NCT07463391","Chinese Classics Recitation Training in Subjective Cognitive Decline","The Effect of Memory Training by Chinese Classics Recitation on Individuals With Subjective Cognitive Decline","Inclusion Criteria:\n\n* Age ≥ 60 years old\n* At least two \"yes\" responses to the following questions are required:\n\n  1. Forgetting where things are placed?\n  2. Unable to recall the names of good friends?\n  3. Unable to follow and recall conversation?\n  4. Subjective memory problems?\n  5. Consider own memory to be worse than others of a similar age?\n\nExclusion Criteria:\n\n* Objective cognitive impairment defined as ≥ 1.5 standard deviations below standardized cognitive testing (e.g., MMSE)\n* Diagnosis of MCI\n* Clinical Dementia Rating (CDR) ≥ 0.5\n* Diagnosis of major depressive disorder\n* Beck Anxiety Inventory score ≥ 16\n* Other medical or neurological conditions that could explain cognitive decline (e.g., vascular dementia, traumatic brain injury)\n* Claustrophobia\n* Contraindications of MRI (e.g., non-MRI-compatible cardiac pacemaker or devices implanted within the past three months)",{"count":387,"type":20},60,[23],"Subjective cognitive decline (SCD) is considered a preclinical condition associated with an increased risk of dementia and Alzheimer's disease. Effective early behavioral interventions remain limited, and the neurobiological mechanisms underlying cognitive training effects are not fully understood, particularly in culturally specific educational contexts.\n\nThis randomized, assessor-blinded, controlled clinical trial will enroll 60 individuals with SCD to evaluate the effects of a six-month structured Chinese Classics recitation training program. Participants will be randomly assigned to either an intervention group or a non-active control group. Assessments will be conducted at baseline, immediately post-intervention, and during annual follow-up.\n\nMultimodal evaluations will include neuropsychological testing, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), blood biomarker profiling, gut microbiota analysis, and fecal metabolomics. The study aims to examine clinical outcomes and explore potential neurobiological and systemic correlates associated with culturally adapted cognitive training.",[391,392],"Subjective Cognitive Decline (SCD)","Subjective Cognitive Decline",[394,395,396,397,398],"subjective cognitive decline","memory training","Chinese Classics","recitation","randomized controlled trial","2026-03-05",{"date":373,"type":36},{"date":402,"type":20},"2026-08-01",{"date":404,"type":20},"2032-12-31",{"name":42,"class":43},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":21,"phases":413,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":44},"100589108","evaluation-of-the-juice-ha-as-an-anti-sarcopenia-100589108","NCT06950125","Evaluation of the JUICE HA® as an Anti-sarcopenia","Inclusion Criteria:\n\n* Participants that have been diagnosed with sarcopenia by a physician and meet the AWGS 2019 criteria for sarcopenia.\n\nExclusion Criteria:\n\n* Participants with a history of severe lower extremity musculoskeletal injuries within the past six months or those who have a fear of blood sampling will be excluded.",{"count":387,"type":20},[23],"This study plans to recruit 60 participants aged 65 years and older who have been diagnosed with sarcopenia by a physician. Participants will be randomly assigned into JUICE HA® supplement and placebo group. All of the participants will be asked to take 15 mL\u002Fday of JUICE HA® supplement or placebo group for 12 weeks. The aim of this trial is to evaluate the potential of JUICE HA® to enhance physiological status (muscle mass and functional fitness) and to improve the quality of life in patients with sarcopenia.",[416],"Sarcopenia in Elderly",[418,419],"sarcopenia","quality of life","2026-02-26",{"date":422,"type":36},"2026-02-27",{"date":424,"type":36},"2025-06-23",{"date":426,"type":20},"2026-03-13",{"name":42,"class":43},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":228,"minAge":161,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":447,"locationsCount":4},"100626554","exploring-the-effects-of-shangshou-daoyin-method-on-improving-sleep-quality-quality-of-life-and-tcm-constitution-in-breast-cancer-patients-with-insomnia-100626554","NCT07437144","Exploring the Effects of Shangshou Daoyin Method on Improving Sleep Quality, Quality of Life, and TCM Constitution in Breast Cancer Patients With Insomnia","Inclusion Criteria:\n\n* Breast cancer patients aged ≥20 years diagnosed with 0-III cancer, without any signs of metastasis or recurrence\n* Cases who have completed surgery, targeted therapy, chemotherapy, or radiotherapy at least 3 months ago.\n* Cases who have started taking anti-hormone inhibitors and traditional Chinese medicine for 3 months.\n* Pittsburgh Sleep Quality Scale (CPSQI) score ≥5.\n* Cases who are willing to participate and complete the consent form.\n\nExclusion Criteria:\n\n* Patients with other cancers.\n* Illiterate\n* Patients with physical disabilities or inability to perform physical activities.\n* Patients diagnosed with mental illness by a physician.",{"count":435,"type":20},76,[23],"Breast cancer patients often experience insomnia and physical imbalances during and after treatment, indirectly affecting their quality of life. Therefore, the sleep quality, quality of life, and TCM constitution of breast cancer patients need to be taken seriously. Oral sleep aids are prone to causing additional side effects; therefore, in addition to medication, non-pharmacological therapies can be used to alleviate the insomnia caused by breast cancer patients, thereby improving their quality of life. Because guided exercises are simple to learn, gentle, safe, and can be performed without time constraints, clinicians can apply them to the care of breast cancer patients. It is hoped that the results of this study can provide a reference for other related research.",[439],"Breast Cancer Patients Diagnosed With Stage 0-III",[441],"Breast cancer、Shangshou Daoyin、Sleep quality、Traditional Chinese medicine constitution、quality of life","2026-02-22",{"date":422,"type":36},{"date":445,"type":20},"2026-03-02",{"date":40,"type":20},{"name":42,"class":43},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":98,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":21,"phases":457,"briefSummary":458,"conditions":459,"keywords":465,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":44},"100612156","feasibility-of-wearables-in-dementia-care-in-rural-taiwan-100612156","NCT07249918","Feasibility of Wearables in Dementia Care in Rural Taiwan","Facilitating the Measurement and Treatment of the Behavioral Symptoms of Dementia (BPSD) and Understanding Caregiver Burden Using Wearable Devices in Rural Taiwan - A Dyadic Feasibility Pilot Study","Inclusion Criteria:\n\n* For participants with dementia:\n\n  1. Clinical diagnosis of probable Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD, based on established diagnostic criteria.\n  2. Presence of at least one prominent behavioral or psychological symptom of dementia (BPSD), including depression, agitation, apathy, or nighttime sleep disturbance.\n  3. Prominent is defined as:\n\n     NPI single-item score ≥ 4 (severity × frequency), or NPI-Q severity score ≥ 2, or PSQI total score ≥ 5 (if sleep disturbance is the main symptom).\n  4. Stable living arrangement or care environment for at least two weeks before enrollment.\n  5. If receiving any pharmacological or non-pharmacological treatments for BPSD, the dosage and frequency must have remained stable for at least two weeks prior to study participation.\n  6. Able and willing to provide informed consent; for those lacking decision-making capacity, consent must be obtained from a legally authorized representative.\n* For primary caregivers:\n\n  1. Adult primary caregiver of the enrolled participant.\n  2. If receiving treatment for caregiver stress, the dosage and frequency must have been stable for at least two weeks before enrollment.\n  3. Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Any medical condition that may increase risk during participation, including:\n\n  1. Retinal disease, active use of photosensitizing medications, recent ocular surgery (within 4 weeks), or photosensitivity disorders (e.g., epilepsy).\n  2. Unstable physical or mental condition deemed unsuitable by investigators, such as acute delirium or active respiratory infection (including COVID-19)",{"count":456,"type":20},20,[23],"Taiwan is becoming a super-aged society, and more older adults are living with Alzheimer's disease. Many people with Alzheimer's experience behavioral and psychological symptoms, such as agitation, sleep problems, or mood changes. These symptoms often lower their quality of life and increase stress for their family caregivers.\n\nThis study will test two wearable devices in people with Alzheimer's and their caregivers. One device, called Geneactiv, is a wristwatch that tracks daily activity and sleep. The other device, called Re-Timer, is a light therapy eyewear that may help improve sleep and mood. Researchers will look at how easy the devices are to use, whether participants are willing to wear them for several weeks, and whether the light therapy helps reduce sleep problems or caregiver stress.\n\nThe study will also compare information from questionnaires with information collected by the devices. The results may help researchers design future studies using wearable tools to better support people living with dementia and their caregivers.",[460,461,462,463,464],"Alzheimer's Dementia","Neuropsychiatric Symptoms Related to Neurodegenerative Disease","Wearable Devices","Caregiver Burden of People With Dementia","Circadian Rhythm",[466,467,468,469,470],"Wearable device","behavioural and psychological symptoms of dementia (BPSD)","Sleep","Alzheimer's dementia","Caregiver Burden","2026-02-09",{"date":473,"type":36},"2026-02-11",{"date":475,"type":36},"2025-11-18",{"date":40,"type":20},{"name":42,"class":43},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":98,"sex":17,"minAge":161,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":21,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":4},"100622573","effects-of-myofascial-chain-tension-modulation-combined-with-scapular-corrective-exercise-on-scapular-movement-performance-and-functional-outcomes-in-tennis-players-with-subacromial-impingement-syndrome-100622573","NCT07385378","Effects of Myofascial Chain Tension Modulation Combined With Scapular Corrective Exercise on Scapular Movement Performance and Functional Outcomes in Tennis Players With Subacromial Impingement Syndrome","Inclusion Criteria:\n\n* Participants were included if they met all of the following conditions:\n\n  1. a VAS score greater than 3 during the Hawkins test (indicating mild to moderate pain),\n  2. at least two positive results among the Hawkins test, Neer test, and painful arch test, and\n  3. a positive result on the mSAT. Only participants who fulfilled all three criteria were enrolled in the study.\n\nExclusion Criteria:\n\n* Participants were excluded if they had a history of clavicle, scapular, or humeral fractures; shoulder dislocation; or rotator cuff surgery; positive results on the cervical compression test, apprehension test, or drop arm test; had received corticosteroid injections within the past three months; had undergone physical therapy within the past six months; or reported a VAS score higher than 9.","35 Years",{"count":486,"type":20},36,[23],"Subacromial Impingement Syndrome (SIS) is characterized by abnormal scapular motion, including decreased upward rotation, increased internal rotation, and excessive anterior tilting, which impair shoulder and arm function. Integrated scapular rehabilitation combines Instrument-Assisted Soft Tissue Mobilization (IASTM) and postural correction exercises. IASTM detects soft tissue restrictions through multidirectional strokes and enhances the pain threshold of myofascial trigger points (MTrPs) via reflex hyperemia. Postural correction exercises aim to strengthen weakened muscles and stretch tight ones to improve stability and posture. The combination of these interventions may enhance scapular stability and dynamic control. This study aimed to investigate the effects of integrated scapular rehabilitation on scapular kinematics, movement correction, functional improvement, and pain management in tennis athletes with SIS. A two-way repeated-measures ANOVA was used to analyze pre- and post-intervention effects.",[490],"Subacromial Impingement Syndrome",[492,493,494],"muscle imbalance","scapular dyskinesis","instrument-assisted soft tissue mobilization","2026-01-27",{"date":497,"type":36},"2026-02-04",{"date":499,"type":20},"2026-02-01",{"date":501,"type":20},"2027-08-31",{"name":42,"class":43},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":98,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":44},"100605590","risk-factors-for-developing-peak-plantar-pressure-during-walking-in-the-diabetic-patients-100605590","NCT07164495","Risk Factors for Developing Peak Plantar Pressure During Walking in the Diabetic Patients","Investigation of the Risk Factors and Establishing a Prediction Model for Developing Peak Foot Pressure During Walking in the Diabetic Patients","Inclusion Criteria:\n\n* diagnosed with type 2 diabetes, at least for five years\n* aged older than 18 years\n* walk independently for at least 10 meter without any assistive device\n\nExclusion Criteria:\n\n* severe deformity in the foot or lower extremity\n* significant neuropathic or surgical diseases that affect normal walking function\n* cognitive dysfunction\n* active foot ulcer",{"count":511,"type":20},120,"The goal of this observational study is to investigate the clinically convenient dynamic and static measurement parameters to identify related risk factors of developing high peak plantar pressure during walking in the type-2 diabetic patients, and then establish a predictive model to estimate the likelihood of excessive plantar pressure.\n\nThe main question it aims to answer is:\n\nWhich clinical measurements may be used as the predictors that increased peak plantar pressure in the type-2 diabetic patients? Participants taking the examinations will understand their own clinally meaningful measurements related to their plantar pressure during walking. Further thorough analysis will be employed to develop a predictive model, aiming to provide potential improvement strategies for preventing diabetic foot ulcers in the future.",[514],"Diabete Type 2",[516,517,518],"Diabetes","Gait","Plantar Pressure","2026-01-26",{"date":521,"type":36},"2026-01-28",{"date":523,"type":36},"2024-10-01",{"date":240,"type":20},{"name":42,"class":43},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":319,"maxAge":18,"enrollmentInfo":534,"targetDuration":4,"studyType":21,"phases":535,"briefSummary":536,"conditions":537,"keywords":539,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":44},"100620894","omega-3-fatty-acids-inflammation-gut-microbiota-in-youth-with-depression-100620894","NCT07363551","Omega-3 Fatty Acids, Inflammation, Gut Microbiota in Youth With Depression","Omega-3 Fatty Acids, Inflammation, Gut Microbiota in Youth With Depression (OMIMYDep)- A Double-blind Randomized Controlled Trial","OMIMYDep","Inclusion Criteria:\n\n* Youth with a DSM-5 diagnosis of MDE\n\nExclusion Criteria:\n\n* Has a recent change in antidepressants or psychotherapy treatment within 4 weeks.\n* Allergic to omega-3 fatty acids",{"count":387,"type":20},[23],"This is a 12 week double blind RCT aimed to investigate the role of omega-3 fatty acids in patients with major depressive disorder",[538],"ADHD",[540],"omega-3, ADHD","2026-01-22",{"date":519,"type":36},{"date":544,"type":36},"2021-06-09",{"date":546,"type":20},"2026-05-31",{"name":42,"class":43},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":556,"maxAge":18,"enrollmentInfo":557,"targetDuration":4,"studyType":21,"phases":558,"briefSummary":559,"conditions":560,"keywords":563,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":573,"locationsCount":44},"100620954","omega-3-fatty-acids-neuroendocrine-and-attention-deficit-hyperactivity-disorder-omneadhd-100620954","NCT07364331","Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD)","Omega- 3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder With (OMNeADHD) A Double Blind Randomized Controlled Trial of High Dose Omega- 3 Fatty Acids in Children and Adolescents With ADHD With Omega- 3 Deficiency.","OMNeADHD","Inclusion Criteria:\n\n1. DSM-5 diagnosis of ADHD\n2. Did not have any changes of ADHD treatment (pharmacological\u002Fpsychological) within 4 weeks of entering the trial.\n3. SNAP-IV inattention subscale \\>=12, or hyperactivity subscale \\>=12, or inattention+ hyperactivity subscales \\>=24\n\nExclusion Criteria:\n\n1. IQ\\\u003C80\n2. Allergic to omega-3\n3. Physical disorders: thyroid function, cancer\n4. Psychiatric comorbidity: SUD, psychotic disorders, bipolar disorder, major depressive disorder","6 Years",{"count":203,"type":20},[23],"This is a 12 week randomized controlled study on the effects of omega-3 fatty acids in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.",[538,561,562],"Children","Adolescents",[564,565,566,567,538,568],"omega-3","epa","dha","children","adolescents",{"date":519,"type":36},{"date":571,"type":36},"2021-09-04",{"date":377,"type":20},{"name":42,"class":43},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":556,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":21,"phases":585,"briefSummary":586,"conditions":587,"keywords":589,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":597,"locationsCount":44},"100621048","omega-3-autism-spectrum-disorder-asd-100621048","NCT07365553","Omega-3, Autism Spectrum Disorder (ASD)","Omega-3 Fatty Acids and Autism Spectrum Disorder (ASD) - A Double-blind Randomized Controlled Trial of Omega-3 Fatty Acids in Youth With ASD","OMeASD","Inclusion Criteria:\n\n* diagnosis of DSM5 ASD made by child and adolescent psychiatrist\n* age 6-17 years-old at the time of enrolment\n* no pharmacotherapy or non-pharmacotherapy adjustment within the past 4 weeks,\n* Signed informed consent.\n\nExclusion Criteria:\n\n* comorbid other psychiatric disorders, including schizophrenia or affective mood disorder (Bipolar and Major Depressive Disorder), or substance use disorder\n* comorbid physical disorders, such as thyroid dysfunction, cerebral palsy, coagulation disorders\n* currently using omega-3 supplements or probiotics\n* allergy to omega-3.","17 Years",{"count":584,"type":20},50,[23],"This is a 12 week study to investigate the effects of omega-3 polyunsaturated fatty acids (PUFAs) in youth with autism spectrum disorder (ASD).",[588],"ASD",[590,591,564],"inflammation","adolescent","2026-01-16",{"date":519,"type":36},{"date":595,"type":36},"2022-07-15",{"date":377,"type":20},{"name":42,"class":43},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":98,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":606,"conditions":607,"keywords":609,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":617,"locationsCount":44},"100617094","study-on-the-use-of-traditional-chinese-medicine-diagnostic-tools-to-assist-in-identifying-the-clinical-characteristics-of-inflammatory-bowel-disease-and-research-on-metabolic-plastids-of-tongue-coating-100617094","NCT07314151","Study on the Use of Traditional Chinese Medicine Diagnostic Tools to Assist in Identifying the Clinical Characteristics of Inflammatory Bowel Disease and Research on Metabolic Plastids of Tongue Coating","Inclusion Criteria:\n\n* Adult patients aged 18 years or older who are able to provide informed consent and comply with the study procedures.\n* Experimental group: Patients with a primary diagnosis of Crohn's disease or ulcerative colitis, defined by ICD-10-CM codes K50-K51.\n* Control group: Individuals without inflammatory bowel disease and without significant gastrointestinal symptoms.\n\nExclusion Criteria:\n\n* Individuals who are unable to provide informed consent or unable to comply with study procedures or questionnaires.\n* Individuals who have undergone major surgery or received chemotherapy or radiotherapy within the past month.\n* Pregnant women.\n* Individuals deemed unsuitable for participation in this study by the attending physician.\n* Control group exclusions:\n\n  * Individuals with any diagnosed psychiatric disorder.\n  * Individuals with any major gastrointestinal disease, such as gastrointestinal malignancy.",{"count":605,"type":20},200,"This study will be conducted at the outpatient clinic of China Medical University hospital. It is expected to enroll two groups of 30 subjects, including the experimental group must meet the clinical diagnosis of IBD, and the control group without IBD and have no obvious gastrointestinal symptoms . This proje ct uses modern TCM diagnostic tools, such as tongue diagnosis instrument, auscul tation instrument, TCM constitution questionnaire, and pulse diagnosis instrument to establish the comparison of physiological and biochemical indicators such as TCM phenotype and laboratory tests data in patients with IBD. Besides, another purpose of this project is to analyze the tongue coating metabolites of patients with IBD by mass spectrometry, and to establish a research model of tongue coating an d metabolomics for patien ts with IBD and the prognosis analysis of acute and remission phases.",[608],"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)",[610],"inflammatory bowel disease, Crohn's disease, ulcerative colitis, gut brain axis, Traditional Chinese medicine (TCM) diagnosis, Tongue diagnosis, Metabolomics","2025-12-23",{"date":613,"type":36},"2026-01-02",{"date":615,"type":36},"2024-02-15",{"date":377,"type":20},{"name":42,"class":43},""]